Taxonomy of Cannabinoids

Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential

Volumn , Issue , 2013, Pages 15-26

  Pate, David W ^a  

^a HortaPharm BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85071779817     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (34)

1. Abadji V, Lin S, Gihall T, Griffen G, Stevenson LA, Pertwee GR, Makriyannis A (R)-methanandamide: A chiral novel anandamide possessing higher potency and metabolic stability. Journal of Medicinal Chemistry 1994;37(12): 1889-1893
2. Adams R, Loewe S, Jelinek e, WoltIH. Tetrahydrocannabinol homologs with marihuana activity. IX. Journal of the Ame6can Chemical Society 1941;63:1971-1976
3. Archer RA, Stark P, Lemberger L. Nabilone. In Mechoulam R, ed. Canllabinaids As Therapelltic Agents. Boca Raton, FL: eRe Press, 1986, pp. 85-103
4. Beltramo M, di Tomaso E, Piomelli D. Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene) tetrahydro-3-(I-naphthalenyl)-2Hpyran-2-one. FEBS Letters 1997;403(3):263-267
5. Beltramo M, Stella N, Calignano A, Lini SY, Makrianllis A, Piomelli D. Functional role of high-affinity anandarnide transport, as revealed by selective inhibition. Science I 997;277(532g): 1094-1 096
6. Ben-Zvi Z, Mechoulam R, Burstein S. Identification through synthesis of an active delta-l (6)-tetrahydrocannabinol metabolite. Journal afthe American Chemical Society 1970;92(11):3468-3469
7. Childers SR, Sexton T, Roy MB. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochemical Pharmacology 1994;47:711-715
8. Compton DR, Martin BR. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the phannacological effect of anandamide in the mouse model of cannabimimetic activity. Journal of Pharmacology and Experimental Therapeutics 1997;283(3): 1138-1143
9. Cravatt B, Prospero-Garcia O, Siuzdak G, Gilula NB, Henriksen SJ, Boger DL, Lerner RA. Chemical characterization of a family of brain lipids that induce sleep. Science 1995;268: 1506-1509
10. Deutsch DG, Omeir R, Arreaza G, Salehani D, Prestwich GO, Huang Z, Howlett A. Methyl arachidonyl fluorophosphonate: A potent irreversible inhibitor of anandamide amidase. Biochemical Pharmacology 1997;53(3):255-260
11. Di Marzo V. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: Biochemistry and possible physiopathological relevance. Biochimico et Biophysica Acto 1998; 1392(2-3): 153-175
12. 1(6) tetrahydrocannabinol. Journal of the American Chemical Society 1966;88:5673-5675
13. Gareau Y, Dutfesne C, Gallant M, Rochette C, Sawyer N, Slipetz DM, Trembley N, Weech PK, Metters KM, Labelle M. Structure-activity relationships of tetrahydrocannabinol analogues on human crumabinoid receptors. Bioorganic Medicinal Chemistrv Letters 1996;6:189-194
14. Haubrich DR, Ward SJ, Baizman E, Bell MR, Bradford J, Ferrari R, Miller M, Perrone M, Pierson AK, Saelens IK, Luttinger D. Pharmacology of pravadoline: A new analgesic agent. Journal of Pharmacology and Experimental Therapeutics 1990;255(2):511-522
15. Hollister, LE. Structure-activity relationships in man of Cannabis constituents, and homologues and metabolites of thetrahydrocannabinoL Plwrmacology 1974;11(1):3-11
16. Hollister LE, Gillespie HK. Delta-8-and delta-9-tetrahydrocannabinol. Clin ical Pharmacology and Therapeutics 1973:14(3):353-357
17. Hollister LE, Richards RK, Gillespie HK. Comparison of tetrahydrocmmabinol and synhexyl in man. Clinical Pharmacology and Therapeutics 1968;9(6):783-791
18. Maccarrone M, van der Stelt M, Rossi A, Veldink GA, Vliegenthart JFG, Agro AF. Anandamide hydrolysis by human cells in culture and brain. Journal of Biological Chemistry 1998;273(48): 32332-32339
19. Mechoulam R, Feigenbaum JJ. Towards cannabinoid drugs. In E11is GP, West GB eds., Progress in medicinal chemistr.v, Volume 24. Amsterdam: Elsevier Science Publishers (Biomedical Division), 1987, pp. 159-207
20. Mechoulam R, Fride E, Di Marzo V. EndocaImabinoids. European Journal of Pharmacology 1998;359(1): 1-18
21. Melvin LS, Milne GM, Johnson MR, Subramaniam 8, Wilken GH, Howlett AC. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: Studies of bicyc1ic cannabinoid analogs. Molecular Pharmacology 1993;44(5): 1008-1015
22. Pate DW. TIle Phytochemistry of Cannabis: Its ecological and evolutionary implications. In Rana11i P. ed., Advances in hemp research. Binghamton, NY: The Haworth Press, 1999, pp. 243-255
23. Patricelli MP, Patterson JE, Boger DL, Cravatt BF. An endogenous sleep-inducing compound is a novel competitive inhibitor of fatty acid amide hydrolase. Bioorganic Medicinal Chemistry Leiters 1998;8:613-618
24. Razdan RK. Structure-activity relationships in cannabinoids. Pharmacological Reviews 1986;38(2):75-149
25. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, et al. SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters 1994;350(2-3):240-244
26. Rinaldi-Carmona M, Barth F, Millan J, Derocq J-M, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, et al. SR 144528, the first potent and selective antagonist of the brain cannabinoid receptor. Journal ofPharmacology and Experimental Therapeutics 1998;284(2):644-650
27. Ryan WJ, Banner WK, Wiley JL, Martin BR, Razdan RK. Potent anandamide analogs: The effect of changing the length and branching of the end penryl chain.Tournai of Medicinal Chemistry 1997;40(22):3617-3625
28. Sheskin T, Hanus L, Slanger J, Vogel Z, Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.Tournai of Medicinal Chemistry 1997;40(5):659-667
29. Showalter VM, Compton DR, Martin BR, Abood:ME. Evaluation of binding in a transfected cell line expressing a peripheral canllabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. Journal of Pharmacology and Experimental Therapeutics 1996;278(3):989-999
30. Terranova J-P, StOlme J-J, Lafon N, Perio A, Rinaldi-Cannona, Le Fur G, Soubrie P. Improvement of memOlY in rodents by the selective C81 cmmabinoid receptor antagonist, SR 141716. Psychopharmacology 1996;126(2):165-172
31. Torii S, Mitsu1110ri K, Inubushi S, Yanagisawa I. The REM sleep-inducing action of a naturally occurring orgaIlic bromine compound in the encephale isole cat. Psychopharmocologio 1973;29(1):65-75
32. Walpole CSJ, Wrigglesworth R, Bevan S, Campbell EA, Dray A, James IF, Perkins.MN, Reid OJ, Winter J. Analogues of capsaisin with agonist activity as novel analgesic agents; Structure-activity studies. 1. The aromatic 'A-region' Journal olMedicinal Chemistry 1993;36:2362-2372
33. Ward A, Holmes B. Nabilone. A preliminary review of its phannacological properties and therapeutic use. Drugs 1985;30(2):127-144
34. Yanagisawa I, Yoshikawa H. A bromine compound isolated from human cerebrospinal fluid. Biochimica et Biophysica Acta 1973;329(2):283-294